ClinicalTrials.gg
RecruitingNCT05851677Updated Sep 17, 2025

Disitamab Vedotin (RC48-ADC) in Breast Cancer

An observational study in Breast Cancer, sponsored by RenJi Hospital. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2025-09-17.

Sponsored by RenJi Hospital · Observational

How we know

From the registry’s dates

  • Started Jun 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
45
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Breast Neoplasms by RenJi Hospital — 15 open to participants now, 17 under way, 2 of them phase 3. Breast Neoplasms · RenJi Hospital.

Started
2023
with 4 others
Observational
7 of 20
6 open now
Primary completion
2027-03
later than 12 of 16 live
Registered
13th of 20
by date

Among the 20 studies in Breast Neoplasms by RenJi Hospital, this one is one of 5 that started in 2023, is one of 7 observational ones, reaches primary completion later than 12 of the 16 other live ones, and was the 13th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

15 of the 20 studies in Breast Neoplasms by RenJi Hospital are open now, in 1 country. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Breast Neoplasms by RenJi Hospital, or all of them as a file.
02

Study summary

To evaluate the efficacy and safety of Disitamab vedotin (RC48-ADC) in patients with breast cancer.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

breast cancer patients with prior or current use of Disitamab vedotin (RC48-ADC)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed breast cancer;
  • Prior or current use of Disitamab vedotin (RC48-ADC);

Exclusion criteria

Exclusion Criteria:

  • Participating in clinical trials involving Disitamab vedotin (RC48-ADC) or not.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
45 participants (estimated)
Patient registry
No

Groups and cohorts

  • RC48-ADC

    RC48-ADC for breast cancer

    Drug: Disitamab vedotin

Interventions

  • recommended but not required regimen of 2.0mg/kg, iv, day1, every 2 weeks

    Also known as: RC48-ADC

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival

    The time from the date of starting Disitamab Vedotin to the date of disease progression as per RECIST version 1.1 or death from any cause, whichever occurs first.

    Time frame: From the date of starting Disitamab vedotin to the date of first documentation of progression or death (up to approximately 1 years)

Secondary outcomes

  1. Adverse events

    Adverse events during Disitamab Vedotin regimen will be assessed according to the NCI CTCAE v5.0.

    Time frame: From the date of starting Disitamab vedotin to the end of the treatment (up to approximately 1 year)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Mar 2027, 45 months after the start.

Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's planned 45 months is below that.

Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2023
First posted
May 10, 2023
StartActual
Jun 1, 2023
Primary completionEst.
Mar 2027
CompletionEst.
Aug 2027
Last update
Sep 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05851677
Lead sponsor
RenJi Hospital
Responsible party
Wenjin Yin (Deputy Chief of Breast Surgery Department, RenJi Hospital) — Principal investigator
First posted
May 10, 2023
Start date
Jun 1, 2023
Primary completion
Mar 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Sep 17, 2025

Study contacts

Wenjin Yin, M.D.
Contact
yinwenjin@renji.com
86(21)68385569
Wenjin Yin, M.D.
principal investigator · Renji Hospital,School of Medicine, Shanghai Jiaotong University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion